CS
BIOTU

Clear Street’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Clear Street’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,291
Closed -$112K – 1444
2022
Q3 		$112K Buy
11,291
+11,284
+161,200% +$112K ﹤0.01% 185
2022
Q2 		$0 Buy
+7
New +$69 ﹤0.01% 1175

Other funds holding BIOTU

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Clear Street's BIOTU Position: Q4 2022 in Review

Clear Street sold out of Biotech Acquisition Company Unit (BIOTU) in Q4 2022, closing a stake of 11,291 shares — an estimated $112K sold.

Clear Street first reported a position in BIOTU in Q2 2022 and held it in 2 quarters. The position peaked at $112K in Q3 2022. 5 funds tracked by Wall St. Rank hold BIOTU as of Q4 2022.

  • Clear Street reported no remaining Biotech Acquisition Company Unit position as of Q4 2022 after selling out during the quarter.
  • Clear Street sold 11,291 Biotech Acquisition Company Unit shares in Q4 2022, an estimated $112K.
  • Clear Street first reported a position in Biotech Acquisition Company Unit in Q2 2022 and held it in 2 quarters.
  • Clear Street's Biotech Acquisition Company Unit position peaked at $112K in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q4 2022.

Based on Clear Street's 13F filing for Q4 2022, filed 13 Feb 2023.